Pharmanovia signs license agreement for Lindis Biotech’s catumaxomab
Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab, a new trifunctional bi-specific monoclonal antibody treatment for…
Oncology
-
-
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso (osimertinib) for approval in…
-
FDA approves Syndax’s Revuforj to treat leukaemia
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or refractory (R/R) acute…
-
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination…
-
FDA approves Azurity Pharmaceuticals’ Danziten for CML treatment
The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only nilotinib formulation that…
-
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa…
-
Kronos mulls ‘strategic alternatives’ after axing cancer drug development
Kronos Bio has discontinued the development of its last remaining clinical asset, istisociclib (KB-0742), after a review of the safety…
-
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a programmed death-ligand 1…
-
Syros stock craters after lead cancer therapy flops in Phase III trial
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial…
-
Ontada and Datavant partner to boost oncology data access
Ontada has entered into a strategic partnership with health data platform Datavant to enable quick access to oncology insights. Under…
